CGEN
Price
$1.29
Change
-$0.12 (-8.51%)
Updated
Apr 4, 02:31 PM (EDT)
Capitalization
129.01M
34 days until earnings call
ORMP
Price
$2.11
Change
-$0.05 (-2.31%)
Updated
Apr 4, 02:45 PM (EDT)
Capitalization
87.83M
54 days until earnings call
Ad is loading...

CGEN vs ORMP

Header iconCGEN vs ORMP Comparison
Open Charts CGEN vs ORMPBanner chart's image
Compugen
Price$1.29
Change-$0.12 (-8.51%)
Volume$299
Capitalization129.01M
Oramed Pharmaceuticals
Price$2.11
Change-$0.05 (-2.31%)
Volume$1K
Capitalization87.83M
CGEN vs ORMP Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. ORMP commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CGEN: $1.41 vs. ORMP: $2.16)
Brand notoriety: CGEN and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 65% vs. ORMP: 53%
Market capitalization -- CGEN: $129.01M vs. ORMP: $87.83M
CGEN [@Biotechnology] is valued at $129.01M. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • CGEN’s TA Score: 4 bullish, 4 bearish.
  • ORMP’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than ORMP.

Price Growth

CGEN (@Biotechnology) experienced а -7.24% price change this week, while ORMP (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.26%. For the same industry, the average monthly price growth was -17.11%, and the average quarterly price growth was -18.88%.

Reported Earning Dates

CGEN is expected to report earnings on May 08, 2025.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-11.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($129M) has a higher market cap than ORMP($87.8M). CGEN has higher P/E ratio than ORMP: CGEN (64.00) vs ORMP (20.91). CGEN YTD gains are higher at: -7.843 vs. ORMP (-10.744). ORMP has higher annual earnings (EBITDA): 9.44M vs. CGEN (-14.41M). ORMP has more cash in the bank: 142M vs. CGEN (103M). ORMP has less debt than CGEN: ORMP (429K) vs CGEN (2.91M). CGEN has higher revenues than ORMP: CGEN (27.9M) vs ORMP (0).
CGENORMPCGEN / ORMP
Capitalization129M87.8M147%
EBITDA-14.41M9.44M-153%
Gain YTD-7.843-10.74473%
P/E Ratio64.0020.91306%
Revenue27.9M0-
Total Cash103M142M73%
Total Debt2.91M429K679%
FUNDAMENTALS RATINGS
CGEN vs ORMP: Fundamental Ratings
CGEN
ORMP
OUTLOOK RATING
1..100
5778
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9585
PRICE GROWTH RATING
1..100
8456
P/E GROWTH RATING
1..100
1942
SEASONALITY SCORE
1..100
1350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (68) in the Pharmaceuticals Other industry is in the same range as CGEN (78) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CGEN’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CGEN (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CGEN’s over the last 12 months.

ORMP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as CGEN (95) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CGEN’s over the last 12 months.

ORMP's Price Growth Rating (56) in the Pharmaceuticals Other industry is in the same range as CGEN (84) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (19) in the Biotechnology industry is in the same range as ORMP (42) in the Pharmaceuticals Other industry. This means that CGEN’s stock grew similarly to ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 29 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SBMBX12.23N/A
N/A
Saratoga Energy & Basic Materials A
NGRRX30.57N/A
N/A
Nuveen International Value I
DLBMX16.02N/A
N/A
MassMutual Small Cap Opps A
CVMAX17.65N/A
N/A
Calvert Emerging Markets Equity A
RTNSX12.04N/A
N/A
Russell Inv Tax-Managed Intl Eq S

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-3.42%
NURPF - CGEN
46%
Loosely correlated
N/A
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
-1.82%
AXON - CGEN
36%
Loosely correlated
-3.35%
BPMC - CGEN
36%
Loosely correlated
-3.22%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-1.82%
BTAI - ORMP
44%
Loosely correlated
-8.54%
INO - ORMP
44%
Loosely correlated
N/A
MBIO - ORMP
44%
Loosely correlated
-9.72%
VERV - ORMP
44%
Loosely correlated
-1.66%
ZNTL - ORMP
43%
Loosely correlated
-7.55%
More